Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy (REFRACT): A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms

Research summary

A prospective,randomised,phase II platform trial for sequential evaluation of experimental treatments versus investigator choice standard therapy (ICT) for patients with relapsed or refractory follicular lymphoma (rrFL). There are three sequential treatment rounds; each has a control arm of ICT and an experimental novel treatment arm. Patients in Round 1 (R1) will be randomised using a 1:1 allocation ratio to receive either ICT or epcoritamab + lenalidomide (experimental treatment). Patients in Rounds 2 (R2) and 3 (R3) (experimental treatments yet to be determined) will be randomised using a 1:4 allocation ratio in favour of the experimental treatment.

Principal Investigator

Dr Toby Eyre

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1005957